Jensen & Associates
we're here to help






our easy information form

Yaz is Produced by Bayer

Bayer HealthCare Pharmaceuticals is the pharmaceutical division of Bayer HealthCare AG and operates under the slogan "Science for a better life - Health through medical progress". They market their products in more than 100 countries and report sales of 10,803 million in 2012. The Bayer HealthCare Pharmaceuticals corporate website explains, "we aim to improve people’s quality of life with our products".

In 2001, the F.D.A. approved Yasmin, which contains a novel progestin called drospirenone. Yaz, which contains drospirenone and a lower dose of estrogen, received agency approval in 2006.

In 2008 the FDA sent Bayer a warning letter for running two false and misleading TV ads about Yaz. The FDA said the ads overstated Yaz's efficacy, promoted it for conditions -- like premenstrual syndrome -- for which it is not approved, and downplayed serious risks associated with the drug. Bayer agreed in February 2009 to spend $20 million on a corrective ad campaign to address the misimpressions from the original campaign.

The FDA sent another warning letter to Bayer in August 2009, this time regarding deviations from quality control standards at a manufacturing plant in Germany that makes drospirenone and other hormone ingredients used in the pills sold in the U.S. The letter said methods used by the facility to calculate variability in ingredients did not meet U.S. standards.

Due to the heavy marketing efforts of Bayer and popularity of Yaz, experts estimate that close to 100 million women were prescribed the drug.  Yaz has been counted among the most widely used birth control drugs in the United States.


Bayer's goal: we aim to improve people’s quality of life with our products.

Since 2004, the FDA has received reports of a significant number of deaths among women using Yaz or Yasmin.

Blood clots can be a risky side effect in women who take Yaz.